An iPSC line derived from a human acute myeloid leukemia cell line (HL-60-iPSC) retains leukemic abnormalities and displays myeloid differentiation defects

Summary

Cancer-derived iPSCs have provided valuable insight into oncogenesis, but human cancer cells can often be difficult to reprogram, especially in cases of complex genetic abnormalities. Here we report, to our knowledge, the first successful generation of an iPSC line from a human immortalized acute myeloid leukemia (AML) cell line, the cell line HL-60. This iPSC line retains a majority of the leukemic genotype and displays defects in myeloid differentiation, thus providing a tool for modeling and studying AML. Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Authors Yamasaki AE, Warshaw JN, Kyalwazi BL, Matsui H, Jepsen K, Panopoulos AD
Journal Stem cell research
Publication Date 2020 Dec;49:102096
PubMed 33370871
PubMed Central PMC8031422
DOI 10.1016/j.scr.2020.102096

Research Projects

Cell Lines